QRG Capital Management Inc. Has $1.55 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

QRG Capital Management Inc. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 26.2% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,749 shares of the medical device company's stock after purchasing an additional 4,716 shares during the quarter. QRG Capital Management Inc.'s holdings in DexCom were worth $1,554,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of DXCM. Sagespring Wealth Partners LLC increased its position in shares of DexCom by 96.1% during the first quarter. Sagespring Wealth Partners LLC now owns 10,552 shares of the medical device company's stock worth $721,000 after acquiring an additional 5,172 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in DexCom by 2.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 238,424 shares of the medical device company's stock worth $16,282,000 after purchasing an additional 5,881 shares during the period. Bank Pictet & Cie Europe AG increased its holdings in DexCom by 5.9% during the 1st quarter. Bank Pictet & Cie Europe AG now owns 117,575 shares of the medical device company's stock worth $8,029,000 after purchasing an additional 6,512 shares in the last quarter. Brighton Jones LLC raised its stake in shares of DexCom by 2.6% in the 1st quarter. Brighton Jones LLC now owns 17,009 shares of the medical device company's stock valued at $1,162,000 after purchasing an additional 427 shares during the period. Finally, Factory Mutual Insurance Co. raised its stake in shares of DexCom by 8.3% in the 1st quarter. Factory Mutual Insurance Co. now owns 521,630 shares of the medical device company's stock valued at $35,622,000 after purchasing an additional 40,000 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DXCM traded down $1.01 during trading hours on Friday, hitting $80.00. The company had a trading volume of 5,238,495 shares, compared to its average volume of 4,357,673. The business has a fifty day moving average of $79.80 and a 200-day moving average of $79.40. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. The firm has a market cap of $31.37 billion, a price-to-earnings ratio of 59.70, a PEG ratio of 1.73 and a beta of 1.46. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.27.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. Canaccord Genuity Group upped their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Citigroup restated a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird cut their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Truist Financial assumed coverage on DexCom in a report on Monday. They issued a "buy" rating and a $102.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

Insider Activity

In related news, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares in the company, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president now owns 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,724 shares of company stock valued at $2,157,034. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.